Aim: Outside of Japan, recombinant-human chorionic gonadotropin (r-hCG) is widely used for the induction of final follicular maturation and early luteinization in women undergoing ovulation induction; whereas in Japan, urine-derived hCG (u-hCG) is predominantly used. The primary objective of this study was to demonstrate the noninferiority of r-hCG to u-hCG for ovulation induction, as assessed by the ovulation rate.
| MATERIALS AND METHODS
This was an open-label, parallel-group, randomized, multicenter, phase III trial (ClinicalTrials.gov. identifier: NCT01653743) in Japanese women who were undergoing ovulation induction with r-hFSH. The study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki, the International Conference on Harmonisation-Good Clinical Practice guidelines, and all applicable regulatory requirements, with all the participants providing written informed consent prior to entry into the trial. The exclusion criteria included infertility due to causes other than hypothalamic-pituitary dysfunction or PCOS, a history of severe ovarian hyperstimulation syndrome (OHSS; classified according to the Japan Reproductive/Endocrine Working Group guidelines 10 ), active thromboembolic disorders, the presence of, or suspected, gonadotropin-or estrogen-dependent malignancy, a history of allergic reaction or hypersensitivity to hCG-or gonadotropin-containing product(s) and/or their excipients, or a contraindication to pregnancy.
| Study participants

| Study treatments and interventions
Women were enrolled at 15 centers in Japan and the trial was conducted between September 2012 and December 2014. The study design is shown in Figure 1 . cle was ≥18 mm; there were no more than three follicles with a mean diameter ≥16 mm; and the serum estradiol level was within an acceptable range for the number of follicles present and was ≤2000 pg/mL.
Women were randomized according to a predefined computergenerated list in random permuted blocks that were stratified by site. 
| Study objectives and end points
The primary objective of this study was to determine whether a single 250 μg s.c. dose of r-hCG was non-inferior to a single 5000 IU i.m.
dose of u-hCG for ovulation induction in Japanese women who had been diagnosed with anovulation or oligo-ovulation secondary to hypothalamic-pituitary dysfunction or PCOS and who were undergoing ovulation induction with r-hFSH. The non-inferiority margin was −20%.
The primary efficacy end point was the ovulation rate, where ovulation was defined as a mid-luteal serum progesterone level ≥5 ng/mL, in all the participants who received hCG and had a serum progesterone level Safety and tolerability, including the incidence and severity of AEs, incidence of OHSS, and local tolerability were also investigated. AEs were classified by their severity and causal relationship to the study treatment. AEs with an onset date occurring on or after hCG use were classed as "treatment-emergent AEs" (TEAEs).
| Statistical analysis
The ovulation rate following a single 5000 IU dose of u-hCG as part of an ovulation induction cycle using r-hFSH in a low-dose, step-up protocol was assumed to be 95%, based on observations from two Japanese trials of r-hFSH for ovulation induction. 11 An ovulation rate of 95% also was observed in a global phase III trial that investigated a single 250 μg dose of r-hCG as part of an ovulation induction cycle using r-hFSH with a similar low-dose, step-up protocol. 2 Assuming that the ovulation rate would be 95% in both arms, 72 evaluable participants (48 treated with r-hCG and 24 with u-hCG) were required to demonstrate that the lower limit of the two-sided 95% CI of the difference in the ovulation rate (r-hCG minus u-hCG) was above the non-inferiority margin of −20%, with at least 90% power. Allowing for a 15% cycle cancelation rate (based on the data from the trials that were used in the previous calculation 11 ), a total of 87 participants needed to be enrolled in order that 72 might be evaluable.
The primary efficacy end point was investigated in the modified intention-to-treat (ITT) population, which included all the participants who were randomized to receive either r-hCG or u-hCG and who completed the primary efficacy assessment. The exact two-sided 95% CI of the difference (Chang and Zhang method 12 ) in ovulation rates was calculated and if the lower bound of the 95% CI was above −20% then non-inferiority was assumed. The secondary efficacy end points were also investigated in the modified ITT population and were reported as percentages with corresponding CIs. The safety analysis was conducted using the safety population, which included all participants who received either r-hCG or u-hCG. 
| Baseline characteristics and demographics
Demographics, baseline characteristics, and infertility history were comparable between the two treatment groups ( Table 1 ). The median age was 31.5 years, the median weight was 52. 
| Efficacy evaluation
For the primary efficacy evaluation, ovulation, defined as a mid-luteal progesterone level ≥5 ng/mL, was reported in all the participants in the modified ITT population (Table 2 ) and the lower limit of the twosided 95% CI of the difference between ovulation rates was −7.8%, which was above the non-inferiority margin of −20%. Therefore, treatment with r-hCG was non-inferior to u-hCG for ovulation induction. Furthermore, for the secondary efficacy evaluation, ovulation, defined as mid-luteal progesterone ≥9.4 ng/mL, was reported in 52 (96.3%) women who received r-hCG and 24 (88.9%) women who received u-hCG ( Table 2 ). The lower limit of the two-sided 95% CI of the difference between ovulation rates was −5.2%, which was above the non-inferiority margin of −20%, also demonstrating noninferiority for this outcome.
The median mid-luteal phase endometrial thickness 5-7 days following hCG administration was comparable between the treatment groups: 11.0 mm and 12.0 mm in the r-hCG and u-hCG treatment groups, respectively. A similar proportion of women had a positive β-hCG pregnancy test 15-20 days following hCG administration: 35.2% of the women who had received r-hCG and 37.0% of the women who had received u-hCG. Biochemical pregnancy was reported in the same proportion of patients in both treatment arms (3.7% in both arms; Table 2 ). The clinical pregnancy rate was also comparable in both groups (29.6% and 33.3% with r-hCG and u-hCG, respectively; Table 2 ).
| Safety evaluation
The incidence of AEs and hCG-related TEAEs was higher in the group that received r-hCG, compared with the group that received u-hCG (Table 3) . At least one AE was experienced pre-hCG administration by 27.8% and 11.1% of the women who received r-hCG and u-hCG, respectively. At least one hCG-related TEAE was experienced by 38.9%
of the women who received r-hCG and 29.6% of the women who received u-hCG. The type and frequency of TEAEs did not represent any new safety concerns, compared with the known safety profile of r-hCG. 5 The most commonly reported TEAEs were OHSS, ovarian cyst, and injection site erythema and pain. Mild, moderate, and severe OHSS were reported by 7.4%, 3.7%, and 3.7% of the patients who were treated with r-hCG and 7.4%, 7.4%, and 0.0% of those who were treated with u-hCG. In one participant from the r-hCG group, OHSS T A B L E 1 Baseline characteristics and demographics (modified intention-to-treat population) BMI, body mass index; r-hCG, recombinant-human chorionic gonadotropin; u-hCG, urine-derived human chorionic gonadotropin.
was considered to be a serious TEAE in one participant who received r-hCG. The incidence of ovarian cyst was identical with r-hCG and u-hCG, occurring in 11.1% of participants in both groups. Injection site erythema was reported by 9.3% and 7.4% of the women who received r-hCG and u-hCG, respectively, and injection site pain was reported by 3.7% and 11.1% of women, respectively. All the injection site AEs were mild in intensity. previously by trials comparing r-hCG with u-hCG, which report significantly fewer AEs with r-hCG. 2, [4] [5] [6] 13, 14 It should be noted that the incidence of AEs pre-hCG administration was also higher in the group that received r-hCG compared with the group that received u-hCG.
| DISCUSSION
Furthermore, the overall incidence of OHSS that was observed in this study (14.8% in both arms) was higher than that reported in 
